Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
+0.27 (0.23%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 114.79 - 119.81
52 week 51.93 - 140.00
Open 117.73
Vol / Avg. 460,606.00/878,651.00
Mkt cap 9.93B
P/E     -
Div/yield     -
EPS -2.05
Shares 84.28M
Beta 1.84
Inst. own 78%
Aug 5, 2015
Q2 2015 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Alnylam Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 23, 2015
Alnylam Pharmaceuticals Inc to Discuss ALN-AT3 Phase 1 Clinical Data - Webcast
Jun 12, 2015
Alnylam Pharmaceuticals Inc Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases Corporate Call
Jun 10, 2015
Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 4, 2015
Alnylam Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 19, 2015
Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference
May 14, 2015
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Alnylam Pharmaceuticals Inc Earnings Call
May 7, 2015
Q1 2015 Alnylam Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -273.92% -712.79%
Operating margin -281.72% -800.97%
EBITD margin - -777.39%
Return on average assets -15.04% -48.05%
Return on average equity -16.74% -59.74%
Employees 256 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
David-Alexandre C Gros M.D. Senior Vice President, Chief Business Officer
Age: 42
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 40
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 56
Bio & Compensation  - Reuters
Amy W. Schulman Director
Age: 54
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters